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WE HAVE PREVIOUSLY estimated a 20% frc-quency of Epstein-Barr virus (EBV) related post-
transplant lymphoproliferative disorders (PTLD) in small 
bowel allograft recipients. I The present study compares 
rates of PTLD among pediatric and adult recipients of 
isolated or composite small bowel allografts. We also report 
PTLD frequency before and after the institution of quan-
titative EBV monitoring and the use of ancillary donor 
bone marrow infusion to facilitate microchimerism. both of 
which began in mid-1994. 
MATERIALS AND METHODS 
The records of patients who underwent small bowel transplantation 
at the University of Pittsburgh Medical Center between May 1990 
and July 1999 were reviewed. Age at transplant. allograft type. 
classification of PTLD. and patient survival were recorded. Actu-
arial survival and actuarial risk of PTLD were calculated using the 
Kaplan-Meier method. Chi-square test or Kruskal-Wallis test, 
followed by Tukey multiple comparison analysis. was used to 
evaluate statistical significance. 
RESULTS 
A total of 127 patients received small bowel allografts either 
alone (n = 48) or in combination with other abdominal 
visceral organs, including liver (n = 79), during the study 
period. These included 73 pediatric and 54 adult patients. 
Twenty-seven study patients developed PTLD for an overall 
frequency of 21 %. Of these PTLD cases, 22 occurred in the 
pediatric and 5 in the adult population (30% vs 9%. P = 
.004). The actuarial frequency of PTLD at 24 months was 
also greater in pediatric (31 %) than in adult (10%) recipi-
ents (P = .01). All five PTLDs in the adult group occurred 
in patients who received composite bowel allografts. The 
only significant association between PTLD frequency and 
type of transplant appeared in adult patients with multivis-
ceral versus isolated bowel transplants (25% vs 3.4%, P = 
.05). No significant difference in PTLD frequency on the 
basis of EBV seropositivity versus seronegativity at time of 
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transplant was seen in adults or children. The overall PTLD 
frequency during the first half of the study (41 %) was 
significantly highcr than during the second half (16%. P = 
.01). Bowel involvement by PTLD was seen in 78% of 
patients. The actuarial survival for PTLD patients was 37'1; 
at 2 years. No difference in survival was seen on the basis of 
polymorphic versus monomorphic appearance of tumors. 
DISCUSSION 
Thcse data indicate that pediatric small bowel recipients 
and adults receiving composite visceral allografts represent 
subpopulations at high risk for PTLD development among 
all bowel allograft recipients. The allograft bowel itself is 
involved in PTLD in a high percentage of cases. reminiscent 
of the situation in lung allograft recipients. 2 The significant 
reduction in PTLD frequency during the second half of our 
study period coincided temporally with both the introduc-
tion of genomic EBV surveillance in peripheral blood3 and 
with the institution of supplemental donor bone marrow 
infusion to enhance microchimerism.4 The relative contri-
butions of these interventions remain to be elucidated. 
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